Nuzenio

Tradingview Anip

Tradingview Anip entity intelligence is not indexable yet because Nuzenio needs more live source-attributed coverage.

topic 10 latest news signals 1 publisher sources 100/100 entity strength

Latest news

ANI Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $109.12, Implies 32% Upside - TradingViewTradingView · Fri, 07 Aug 2026 21:20:07 GMTANIP: Record Q2 revenue and EBITDA, with rare disease and generics fueling strong growth - TradingViewTradingView · Fri, 07 Aug 2026 14:09:23 GMTANI Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingViewTradingView · Fri, 07 Aug 2026 13:31:41 GMTANIP: Q2 2026 delivered 26% revenue growth, led by Rare Disease and Cortrophin Gel's 43% surge - TradingViewTradingView · Fri, 07 Aug 2026 11:58:20 GMTANI Pharmaceuticals 2026: Revenue $266.04M, EPS $1.05— 10-Q Summary - TradingViewTradingView · Fri, 07 Aug 2026 11:11:00 GMTANIP: Q2 2026 revenue rose 25.9% to $266M, led by Rare Disease and Brands, with strong cash reserves - TradingViewTradingView · Fri, 07 Aug 2026 11:03:14 GMTANIP: Record Q2 2026 revenue growth and strong Rare Disease performance drive reaffirmed guidance - TradingViewTradingView · Fri, 07 Aug 2026 11:01:35 GMTANIP Q2'26 Earnings: EPS estimate is 2.04 USD - TradingViewTradingView · Thu, 06 Aug 2026 11:00:30 GMT

Timeline

Fri, 07 Aug 2026 21:20:07 GMTANI Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $109.12, Implies 32% Upside - TradingView
Fri, 07 Aug 2026 14:09:23 GMTANIP: Record Q2 revenue and EBITDA, with rare disease and generics fueling strong growth - TradingView
Fri, 07 Aug 2026 13:31:41 GMTANI Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary - TradingView
Fri, 07 Aug 2026 11:58:20 GMTANIP: Q2 2026 delivered 26% revenue growth, led by Rare Disease and Cortrophin Gel's 43% surge - TradingView
Fri, 07 Aug 2026 11:11:00 GMTANI Pharmaceuticals 2026: Revenue $266.04M, EPS $1.05— 10-Q Summary - TradingView
Fri, 07 Aug 2026 11:03:14 GMTANIP: Q2 2026 revenue rose 25.9% to $266M, led by Rare Disease and Brands, with strong cash reserves - TradingView

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Tradingview Anip.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

1 distinct publisher/source names are currently connected to this entity page.